Pharmacy Technician PTCB Practice Test

Capital lettering (A) does not provide a noticeable difference between drug names and can still result in confusion, so it is not recommended by the FDA, ISMP, and TJC. Italicized lettering (B) may not be easily legible for some individuals and can also make it difficult to distinguish between similar looking drug names. Special lettering (C) is not considered a standard font and can introduce confusion instead of preventing it. Tall Man lettering (D) is encouraged because it emphasizes the portion of the drug name that is unique and helps to differentiate look-alike/sound-alike drug names from one another. This reduces the likelihood of medication errors and improves patient safety.